Lung Cancers Today
Advertisement
The study participants include those who have had at least one first-degree relative diagnosed with lung cancer.
The organization also granted priority review, breakthrough designation, and orphan drug designation to the application.
Sophie Poznanski, PhD, shares insights from her ASCO 2025 presentation on the multifunctional antibody modality.
The study compared results from North America with global results by high-income and low- or middle-income countries.
Mariano Provencio, MD, PhD, presented the results of CheckMate 77T as a late-breaking abstract at ASCO 2025.
Cheryl Czerlanis, MD, shares insights from the session on lung cancer screening that she chaired at ASCO 2025.
Phase 2 of the study investigated the targeted therapy in treatment-naive patients with stage III ALK-positive disease.
Palliative care researchers discuss differences in lung cancer treatment disparities across Hispanic patient subgroups.
Helena Yu, MD, discusses research updates from REZILIENT1 that were presented at ASCO 2025.
Coral Olazagasti, MD, and Maria Velez, MD, MS, reflect on the opportunities at the ASCO Annual Meeting.
Charles Rudin, MD, PhD, presented the data at the 2025 American Society of Clinical Oncology Annual Meeting.
Jennifer Carlisle, MD, discusses amivantamab, and the multidimensional impact of toxicity management at ASCO 2025.
Ivonescimab plus chemotherapy “demonstrated a statistically significant and clinically meaningful improvement” in PFS.
Coral Olazagasti, MD, shares why the ASCO Annual Meeting is a critical time to bring the field together.
Dr. Singhi unpacks the thoracic oncology data and highlights coming up at this year's ASCO Annual Meeting.
Stephen V. Liu, MD, shares what he sees as the key upcoming highlights in thoracic oncology at the ASCO Annual Meeting.
Lurbinectedin plus atezolizumab demonstrated a “clinically meaningful benefit” in patients with ES-SCLC.
Eric Singhi, MD, discusses the recent FDA approval and explains the associated new biomarker testing considerations.
Mara Antonoff, MD, explains the nuances of determining if a patient with oligometastatic disease is a candidate for surgery.
The study is evaluating if hydrogen peroxide in exhaled breath condensate can be used as a biomarker for lung cancer.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.